Medicines Co. Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
G***** c******* t* c**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 2.100% | 2.127% | 15.301% | 12.753% | -13.064% | -5.517% | -30.049% |
| Opko Health Inc. | 2.520% | -2.290% | 6.667% | 15.274% | 17.410% | -29.655% | -60.627% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | 0.600% | 4.403% | 0.606% | -11.230% | -15.306% | -37.594% | -35.659% |
Comments
News
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Revolution Medicines (NASDAQ: RVMD) spent most of its history as a publicly traded company -- that's since 2020 -- trading for less than $50 a share. The company offers a new approach to oncology
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Most clinical-stage biotechs are small-cap companies. That makes sense. Not only can it take years -- sometimes over a decade -- to develop novel medicines, but it is also a very risky endeavor
This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested
The June 10 IPO of Parabilis Medicines (NASDAQ: PBLS) closed up 58% from its $20 offer price. Two days later, Space Exploration Technologies, the largest IPO in history, finished its debut up just